Modified mRNA Vaccines for Infectious Diseases
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but if you are on immunosuppressants or immune-modifying drugs, you may not be eligible to participate. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the treatment Modified mRNA Vaccines for Infectious Diseases?
Research shows that mRNA vaccines, like those used for COVID-19, are highly effective in preventing viral infections. They work by teaching the body to recognize and fight viruses, leading to strong and lasting immune responses. This technology has been successfully used in vaccines for other diseases, suggesting it could be effective for the treatments in this trial.12345
What safety data exists for modified mRNA vaccines in humans?
Studies on mRNA vaccines, like mRNA-1273 for COVID-19, show they are generally safe in humans, with common side effects being mild, such as fatigue and chills. Some studies noted a higher risk of certain manageable heart-related issues compared to flu vaccines, but overall, mRNA vaccines have a lower risk of serious side effects.678910
How do modified mRNA vaccines for infectious diseases differ from other treatments?
Modified mRNA vaccines like mRNA-1010, mRNA-1273, mRNA-1345, and mRNA-1647 are unique because they use a piece of genetic material to instruct cells to produce a protein that triggers an immune response, mimicking a viral infection without using the live virus. This approach allows for rapid production and adaptation to emerging infectious diseases, offering a flexible and potentially more effective alternative to traditional vaccines.15111213
What is the purpose of this trial?
The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.
Eligibility Criteria
Healthy adults aged 18-75 (18-50 for certain vaccines) with a BMI of 18 to 35 can join. They shouldn't plan to get other vaccines within a month of the study, have severe allergies to FLUAD's components, recent blood donations, or immunosuppressant use. Those who've had COVID-19 or flu shots recently are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intramuscular injections of mRNA vaccines or FLUAD®
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- FLUAD®
- mRNA-1010
- mRNA-1273
- mRNA-1345
- mRNA-1647
Find a Clinic Near You
Who Is Running the Clinical Trial?
ModernaTX, Inc.
Lead Sponsor
Dr. Stephen Hoge
ModernaTX, Inc.
Chief Medical Officer
MD from Harvard Medical School
Stéphane Bancel
ModernaTX, Inc.
Chief Executive Officer since 2011
MBA from Harvard Business School, MSc in Engineering from École Centrale Paris